Literature DB >> 8443313

Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS.

C J Fichtenbaum1, D J Ritchie, W G Powderly.   

Abstract

Cryptosporidiosis in patients with AIDS often leads to a severe wasting illness that is difficult to treat. Recent reports suggest that paromomycin may be useful in the treatment of intestinal cryptosporidiosis. We reviewed our experience using paromomycin for the treatment of cryptosporidiosis in seven patients with AIDS. All patients received paromomycin (500 mg orally every 6 hours) for an average of 11.7 days. The mean follow-up period was 3.2 months. All patients had an initial response to paromomycin that was characterized by a decrease in frequency of diarrheal episodes, stabilization of body weight, and/or eradication of cryptosporidia from the stool. The mean number of diarrheal episodes decreased from 10.9 to 1.7 daily. Stabilization or increase in body weight was noted for five of seven patients, and eradication of oocysts was documented for three patients. Relapses or recurrences were noted for three patients. Treatment with paromomycin was well tolerated by all patients with the exception of two, who experienced nausea and abdominal discomfort. Thus, paromomycin appears to be a promising agent for treatment of acute cryptosporidiosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443313     DOI: 10.1093/clind/16.2.298

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Confirmation of the prophylactic value of paromomycin in a natural outbreak of caprine cryptosporidiosis.

Authors:  E H Johnson; J J Windsor; D E Muirhead; G J King; R Al-Busaidy
Journal:  Vet Res Commun       Date:  2000-02       Impact factor: 2.459

2.  Human intestinal and biliary cryptosporidiosis.

Authors:  Xian-Ming Chen; Nicholas F LaRusso
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

3.  Clinical and microscopical features of small-intestinal microsporidiosis in patients with AIDS.

Authors:  P Caramello; G Mazzucco; M Romeo; A Ullio; G DeRosa; A Lucchini; B Forno; T Brancale; A Macor; C Preziosi
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

4.  Synergistic anticryptosporidial potential of the combination alpha-1-antitrypsin and paromomycin.

Authors:  J R Forney; S Yang; M C Healey
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

5.  Detection of Cryptosporidium parvum DNA in formed human feces by a sensitive PCR-based assay including uracil-N-glycosylase inactivation.

Authors:  P Gobet; J C Buisson; O Vagner; M Naciri; M Grappin; S Comparot; G Harly; D Aubert; I Varga; P Camerlynck; A Bonnin
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

Review 6.  Parasitic infections of the small intestine.

Authors:  J Jernigan; R L Guerrant; R D Pearson
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

7.  Evaluation of curative anticryptosporidial activity of paromomycin in a dexamethasone-treated rat model.

Authors:  R Verdon; J Polianski; C Gaudebout; C Marche; L Garry; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Cryptosporidium parvum-specific CD4 Th1 cells from sensitized donors responding to both fractionated and recombinant antigenic proteins.

Authors:  Maria Angeles Gomez Morales; Raffaella Mele; Alessandra Ludovisi; Fabrizio Bruschi; Fabio Tosini; Rachele Riganò; Edoardo Pozio
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

Review 9.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

10.  Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study.

Authors:  R Mancassola; J M Reperant; M Naciri; C Chartier
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.